Like Metformin, Eplerenone, and Losartan, Empagliflozin Switches Off mTOR and Switches On SIRT1 and AMPK
williamhbestermannjrmd.substack.com
That is why empagliflozin slows progression of chronic kidney disease by a third. This effect is not related to glucose levels and these disease modifying medications don’t merely lower the risk factor. They protect cells and organs. Doesn’t that mean that protocols combining these drugs are critical elements of best practice?
Like Metformin, Eplerenone, and Losartan, Empagliflozin Switches Off mTOR and Switches On SIRT1 and AMPK
Like Metformin, Eplerenone, and Losartan, Empagliflozin Switches Off mTOR and Switches On SIRT1 and AMPK
Like Metformin, Eplerenone, and Losartan, Empagliflozin Switches Off mTOR and Switches On SIRT1 and AMPK
That is why empagliflozin slows progression of chronic kidney disease by a third. This effect is not related to glucose levels and these disease modifying medications don’t merely lower the risk factor. They protect cells and organs. Doesn’t that mean that protocols combining these drugs are critical elements of best practice?